TY - JOUR
T1 - Maintained Reduction of Intraocular Pressure by Prostaglandin F2α-1-Isopropyl Ester Applied in Multiple Doses in Ocular Hypertensive and Glaucoma Patients
AU - Camras, Carl B.
AU - Siebold, Earlene C.
AU - Lustgarten, Jacqueline S.
AU - Serle, Janet B.
AU - Frisch, Sandford C.
AU - Podos, Steven M.
AU - Bito, Laszlo Z.
N1 - Funding Information:
Supported in part by grants EY07865, EY05852, EY01867, EY06657, and EYOO333 from the National Eye Institute, Bethesda, Maryland; an unrestricted grant from Research to Prevent Blindness Inc, New York, New York; a grant-in-aid from the National Society to Prevent Blindness, Inc, Dr. Bito has a proprietary interest in the development of prostaglandins or other eicosanoids and their derivatives for the treatment of ocular hypertension and glaucoma through relevant patents and patent applications that were developed, in part, under research grant EYOO333 from the National Eye Institute, and were assigned, according to the National Institutes of Health directives, to the Trustees of Columbia University, New York, New York.
PY - 1989
Y1 - 1989
N2 - In a randomized, double-masked, placebo-controlled study, 0.25 μg (n = 11) or 0.5 μg (n = 13) of prostaglandin F2α-1-isopropyl ester (PGF2α-IE) was applied topically twice daily for 8 days to one eye of ocular hypertensive or chronic open-angle glaucoma patients. Compared with contralateral, vehicle-treated eyes, PGF2α-IE significantly (P < 0.05) reduced intraocular pressure (IOP), beginning 4 hours after the first 0.5-μg dose and lasting at least 12 hours after the fourteenth dose, with a significant (P < 0.005) mean reduction of 4 to 6 mmHg maintained throughout the last day of therapy with either dose. A contralateral effect was not observed. Mean tonographic outflow facility was significantly (P < 0.05) higher in PG-treated compared with vehicle-treated eyes (0.17 ± 0.02 versus 0.12 ± 0.01 μl/minute/mmHg, respectively; ± standard error of the mean) for the 0.5-μg dose. Conjunctival hyperemia reached a maximum at 30 to 60 minutes after PGF2α-IE application. Some patients reported mild irritation lasting several minutes after some doses. Visual acuity, accommodative amplitude, pupillary diameter, aqueous humor flare, anterior chamber cellular response, Schirmer's test, pulse rate, and blood pressure were not significantly altered. Our findings show that PGF2α-IE is a potent ocular hypotensive agent and a promising drug for glaucoma therapy.
AB - In a randomized, double-masked, placebo-controlled study, 0.25 μg (n = 11) or 0.5 μg (n = 13) of prostaglandin F2α-1-isopropyl ester (PGF2α-IE) was applied topically twice daily for 8 days to one eye of ocular hypertensive or chronic open-angle glaucoma patients. Compared with contralateral, vehicle-treated eyes, PGF2α-IE significantly (P < 0.05) reduced intraocular pressure (IOP), beginning 4 hours after the first 0.5-μg dose and lasting at least 12 hours after the fourteenth dose, with a significant (P < 0.005) mean reduction of 4 to 6 mmHg maintained throughout the last day of therapy with either dose. A contralateral effect was not observed. Mean tonographic outflow facility was significantly (P < 0.05) higher in PG-treated compared with vehicle-treated eyes (0.17 ± 0.02 versus 0.12 ± 0.01 μl/minute/mmHg, respectively; ± standard error of the mean) for the 0.5-μg dose. Conjunctival hyperemia reached a maximum at 30 to 60 minutes after PGF2α-IE application. Some patients reported mild irritation lasting several minutes after some doses. Visual acuity, accommodative amplitude, pupillary diameter, aqueous humor flare, anterior chamber cellular response, Schirmer's test, pulse rate, and blood pressure were not significantly altered. Our findings show that PGF2α-IE is a potent ocular hypotensive agent and a promising drug for glaucoma therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024425601&partnerID=8YFLogxK
U2 - 10.1016/S0161-6420(89)32717-5
DO - 10.1016/S0161-6420(89)32717-5
M3 - Article
C2 - 2780003
AN - SCOPUS:0024425601
SN - 0161-6420
VL - 96
SP - 1329
EP - 1337
JO - Ophthalmology
JF - Ophthalmology
IS - 9
ER -